Mounjaro Medication: What It Is and How It Works

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This page belongs to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetics underneath them into plain language. Explore the full Peptides & GLP-1 library.

What kind of medication Mounjaro is

Mounjaro is Eli Lilly's brand of tirzepatide, and it belongs to a newer class than the single-target GLP-1 drugs that came before it. Tirzepatide is a GIP/GLP-1 dual agonist: a single peptide that engages both the GIP and GLP-1 receptors. Its approval footprint is specific. Mounjaro is FDA-approved for type 2 diabetes (2022), while the same active ingredient under the Zepbound name is FDA-approved for chronic weight management (2023) and for obstructive sleep apnea in adults with obesity (2024, based on SURMOUNT-OSA).

How the medication works in the body

GLP-1 receptor agonists and GIP/GLP-1 dual agonists act on appetite regulation, satiety signaling, and gastric emptying. Rather than relying on willpower, they lower caloric intake through mechanism-mediated changes. How much body weight or glucose shifts depends on the specific compound, dose, adherence, and individual factors. In FDA-approved weight-management use, dosing is titrated upward from a starting amount across several weeks per each product's label.

The evidence behind the medication

Understanding a medication means knowing where its data comes from. For tirzepatide, the SURMOUNT and SURPASS programs are central. The wider GLP-1 class is informed by STEP and SUSTAIN (semaglutide), AWARD (dulaglutide), and LEAD and LEADER (liraglutide). Effect sizes on body weight, A1C, and cardiovascular endpoints vary by population, dose, and primary endpoint.

Where to find the findings

These results are published in sources such as The New England Journal of Medicine, The Lancet, and The Lancet Diabetes & Endocrinology. The outcomes most relevant to any one person are most reliably identified with a healthcare provider rather than pulled from a single headline.

Safety limits and cautions

GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and they are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal, nausea, vomiting, diarrhea, constipation, and usually peak during dose escalation. Rarer serious events include pancreatitis, gallbladder disease, and acute kidney injury in the setting of dehydration.

The genetics upstream of the medication

A medication acts on a body that is genetically unique. Variants in FTO (linked to appetite regulation and adiposity set-point), GLP1R (the GLP-1 receptor gene itself), MC4R (central to energy balance and satiety), and TCF7L2 (tied to glucose homeostasis and GLP-1 secretion) shape the terrain a clinician prescribes into. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights. It does not predict response to any compound; it maps the ground. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

How it compares within its drug class

Placing the medication in context helps explain the attention it draws. Earlier GLP-1 drugs targeted a single receptor; tirzepatide engages two, GIP and GLP-1, which is the structural feature that distinguishes it within the class. That does not automatically make it the right choice for any given person, but it is why the compound is discussed as a distinct step rather than a minor variation.

Comparison across the class is genuinely nuanced. Effect sizes differ by trial, dose, and endpoint, side-effect profiles land differently, and approvals cover different indications. A single-target agonist may suit one situation better and a dual agonist another. Those trade-offs are the province of a prescriber weighing an individual's history, not a ranking that holds for everyone. Understanding the medication, then, means understanding where it sits among alternatives rather than treating it as a standalone answer.

Frequently Asked Questions

What is the Mounjaro medication?

Mounjaro is Eli Lilly's brand of tirzepatide, a GIP/GLP-1 dual agonist that activates both receptors with one peptide. It is FDA-approved for type 2 diabetes from 2022, while the same molecule as Zepbound is approved for chronic weight management from 2023 and obstructive sleep apnea in adults with obesity from 2024.

How does the medication work?

It acts on the GLP-1 pathway to raise satiety, slow gastric emptying, and reduce appetite, lowering caloric intake through mechanism rather than discipline. The degree of effect depends on compound, dose, adherence, and individual factors, and FDA-approved dosing titrates upward per the product label. Discuss mechanism and fit with a qualified healthcare provider.

Who should not take this medication?

It is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and it is not recommended in pregnancy or breastfeeding without provider direction. Caution also applies with severe gastrointestinal disease or a pancreatitis history. Review your full history with a provider.

Can genetics predict how I will respond to it?

No. The Precision Peptide Genetic Test does not predict response to Mounjaro or any medication. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology, offering upstream context that applies across every GLP-1 pathway compound a clinician might consider.

Keep reading across the PlexusDx Education Hub. Return to the Peptides & GLP-1 library.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.